ReviewNature reviews. Urology2013
Evolution of advanced technologies in prostate cancer radiotherapy.
Review in Nature reviews. Urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03254420 (Randomized Phase II Study Evaluating Late Toxicity Following Intensity-Modulated Radiotherapy and Two Image-Guided Strategies With Corresponding Treatment Margins.), which is not on this map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Phase II Study Evaluating Late Toxicity Following Intensity-Modulated Radiotherapy and Two Image-Guided Strategies With Corresponding Treatment Margins. (RCMIGI)
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities.American journal of clinical oncology · 2018Pooled it
- Resistance to Radiotherapy in Cancer.Diseases (Basel, Switzerland) · 2025Review
- Molecular tumor volume on PSMA PET/CT is an independent imaging biomarker associated with progression-free survival in patients with oligorecurrent prostate cancer.American journal of nuclear medicine and molecular imaging · 2025Article
- Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors.Frontiers in immunology · 2025Review
- Observational
- Challenges and opportunities to integrate artificial intelligence in radiation oncology: a narrative review.Ewha medical journal · 2024Review
- Article
- Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate Cancer.International journal of particle therapy · 2024Article
- Repeatability, reproducibility, and the effects of radiotherapy on radiomic features of lowfield MR-LINAC images of the prostate.Frontiers in oncology · 2024Article
- The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer.Current oncology (Toronto, Ont.) · 2023Review
- The role of image-guided radiotherapy in prostate cancer: A systematic review and meta-analysis.Clinical and translational radiation oncology · 2023Review
- Cone-beam CT delta-radiomics to predict genitourinary toxicities and international prostate symptom of prostate cancer patients: a pilot study.Scientific reports · 2022Article
- Demystifying radiation oncology clinical trial concerns for protocol scientific review and institutional review board committee members.Contemporary clinical trials communications · 2022Review
- Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment.Frontiers in oncology · 2022Review
- Salvage therapy for prostate cancer after radical prostatectomy.Nature reviews. Urology · 2021Review
- Landscape of Carbon Ion Radiotherapy in Prostate Cancer: Clinical Application and Translational Research.Frontiers in oncology · 2021Article
- Volumetric-Modulated Arc Radiotherapy with Daily Image-Guidance Carries Better Toxicity Profile for Higher Risk Prostate Cancer.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Article
- A Comparative Study on the Effects of PostoperativeJournal of multidisciplinary healthcare · 2020Article
- Is prostate specific antigen (PSA) density necessary in selecting prostate cancer patients for active surveillance and what should be the cutoff in the Asian population?Prostate international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional treatment options for clinically localized, low-risk prostate cancer include radical prostatectomy, external-beam radiotherapy (EBRT) and low-dose-rate brachytherapy. Advances in image-guided radiotherapy (IGRT) since the 1980s, the development of intensity-modulated radiotherapy (IMRT) during the 1990s and evidence from radiobiological models--which support the use of high doses per fraction--have developed alongside novel advanced radiotherapy modalities that include high-dose-rate brachytherapy (HDR-BT), stereotactic body radiotherapy (SBRT) and proton beam therapy. The relationship between the outcomes of and toxicities experienced by patients with prostate cancer treated with HDR-BT, SBRT and particle-beam therapy should provide urologists and oncologists an understanding of the continually evolving technology in prostate radiotherapy. On the basis of published evidence, conventionally fractionated EBRT with IMRT is considered the standard of care over conventional 3D conformal radiotherapy, whereas HDR-BT boost is an acceptable treatment option for selected patients with intermediate-risk and high-risk prostate cancer. SBRT and proton therapy should not be used for patients (regardless of disease risk group) outside the setting of a clinical trial. Finally, comparative effectiveness research should be conducted to provide a framework for evaluating advanced radiotherapy technologies by comparing the benefits and harms of available therapeutic options to optimize the risk:benefit ratio and improve cost effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.